Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Cancer Res. 2017 Mar 9;77(9):2292–2305. doi: 10.1158/0008-5472.CAN-16-2832

Fig. 7. Synergistic effects of poly-IC and nutlin-3a in B16 treatment are mediated through reversing immunosuppression and augmenting polyfunctional CTLs in the TME.

Fig. 7

B16 tumors established s.c. in WT mice were first treated i.t. with poly-IC or PBS, followed with nutlin-3a or PBS. At 16 days post-tumor inoculation, mice were euthanized and immune cell composition, activation status, and effector function among all treatment groups of the B16 TME were analyzed. A. TILeus were examined via FACS. B. MDSC subset composition of M-MDSCs and G-MDSCs in different treatment groups was examined via FACS. C. MHC II+ cell percentage and relative MHC II expression among CD11b+ myeloid cells in different treatment groups were determined via FACS. D. TILeus-CD8 and CD4 T cell composition in different treatment group of the B16 TME was determined via FACS. E. Effector cytokine producing TILeu-CD8+ T cells were determined via FACS following intracellular staining and presented in pie chart showing the composition of cytokine producing cells among total TILeu-CD8 cells. Data are presented as mean ± SEM. n = 3–6. Experiments were repeated 2–3 times with similar results. ** p < 0.01, *** p < 0.001, Student’s t-test.